BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders.

The Company’s lead drug candidate is BLU-5937 being developed for the treatment of chronic cough. 

In November 2018, the Company announced positive top-line results from the clinical Phase 1 study for BLU-5937, in which BLU-5937 was shown to be safe and well tolerated. The benign side effect profile, in combination with the anti-tussive effect demonstrated in several preclinical studies, further reinforces the Company’s position that BLU-5937 has the potential to be a best-in-class therapeutic for refractory chronic cough patients. Based on the positive data from the Phase 1 study, BELLUS Health expects to initiate a clinical Phase 2 study for BLU-5937 in patients with refractory unexplained chronic cough in mid-2019, with top-line results anticipated in mid-2020. Refractory chronic cough is a significant unmet medical need with no currently approved treatments.

BELLUS Health is based in Laval, Quebec and its shares trade under the ticker BLU on the Toronto Stock Exchange.

Share this

Sign up for email alerts

Email Address *
 
Enter the code shown above.